Tenax Therapeutics Stock Price, News & Analysis (NASDAQ:TENX)

$0.25 -0.09 (-26.57 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$0.25
Today's Range$0.22 - $0.29
52-Week Range$0.22 - $0.79
Volume1.63 million shs
Average Volume284,350 shs
Market Capitalization$9.46 million
P/E Ratio-0.16
Dividend YieldN/A
Beta1.46

About Tenax Therapeutics (NASDAQ:TENX)

Tenax Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company's main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. Levosimendan represents therapeutic modalities for the treatment of Low Cardiac Output Syndrome (LCOS), septic shock and other critical care conditions. The therapeutic effects of levosimendan are mediated through increased cardiac contractility by calcium sensitization of troponin C, resulting in a positive inotropic effect, which is not associated with substantial increases in oxygen demand; opening of potassium channels in the vasculature smooth muscle, resulting in a vasodilatory effect on all vascular beds, and opening of mitochondrial potassium channels in cardiomyocytes, resulting in a cardioprotective effect.

Receive TENX News and Ratings via Email

Sign-up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TENX
CUSIPN/A
Phone919-806-4414

Debt

Debt-to-Equity RatioN/A
Current Ratio10.43%
Quick Ratio10.43%

Price-To-Earnings

Trailing P/E Ratio-0.159423076923077
Forward P/E Ratio-0.71
P/E GrowthN/A

Sales & Book Value

Annual Sales$40,000.00
Price / Sales175.58
Cash FlowN/A
Price / CashN/A
Book Value$0.61 per share
Price / Book0.41

Profitability

Trailing EPS($1.56)
Net Income$-43,920,000.00
Net MarginsN/A
Return on Equity-89.80%
Return on Assets-70.67%

Miscellaneous

Employees11
Outstanding Shares28,240,000

Tenax Therapeutics (NASDAQ:TENX) Frequently Asked Questions

What is Tenax Therapeutics' stock symbol?

Tenax Therapeutics trades on the NASDAQ under the ticker symbol "TENX."

When did Tenax Therapeutics' stock split? How did Tenax Therapeutics' stock split work?

Shares of Tenax Therapeutics reverse split on Monday, February 26th 2018. The 1-20 reverse split was announced on Friday, February 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 23rd 2018. An investor that had 100 shares of Tenax Therapeutics stock prior to the reverse split would have 5 shares after the split.

How were Tenax Therapeutics' earnings last quarter?

Tenax Therapeutics Inc (NASDAQ:TENX) released its quarterly earnings data on Tuesday, December, 15th. The specialty pharmaceutical company reported ($2.60) earnings per share for the quarter, beating the consensus estimate of ($2.80) by $0.20. View Tenax Therapeutics' Earnings History.

Where is Tenax Therapeutics' stock going? Where will Tenax Therapeutics' stock price be in 2018?

1 equities research analysts have issued 1-year target prices for Tenax Therapeutics' shares. Their forecasts range from $50.00 to $50.00. On average, they anticipate Tenax Therapeutics' stock price to reach $50.00 in the next twelve months. View Analyst Ratings for Tenax Therapeutics.

Who are some of Tenax Therapeutics' key competitors?

Who are Tenax Therapeutics' key executives?

Tenax Therapeutics' management team includes the folowing people:

  • Ronald R. Blanck, Independent Chairman of the Board (Age 74)
  • Michael B. Jebsen CPA, President, Interim Chief Executive Officer, Chief Financial Officer (Age 44)
  • Douglas Hay Ph.D., Executive Vice President - Regulatory Affairs
  • Doug Randall, Executive Vice President - Business and Commercial Operations
  • Paula Bokesch, Chief Medical Officer
  • James Mitchum, Director (Age 62)
  • Gerald T. Proehl, Director (Age 58)
  • Anthony DiTonno, Independent Director (Age 68)
  • Gregory Pepin, Independent Director (Age 32)
  • Chris A. Rallis, Independent Director (Age 61)

Who owns Tenax Therapeutics stock?

Tenax Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Anson Funds Management LP (2.15%). Company insiders that own Tenax Therapeutics stock include Gerald T Proehl and Ronald R Blanck. View Institutional Ownership Trends for Tenax Therapeutics.

Who bought Tenax Therapeutics stock? Who is buying Tenax Therapeutics stock?

Tenax Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Anson Funds Management LP. Company insiders that have bought Tenax Therapeutics stock in the last two years include Gerald T Proehl and Ronald R Blanck. View Insider Buying and Selling for Tenax Therapeutics.

How do I buy Tenax Therapeutics stock?

Shares of Tenax Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tenax Therapeutics' stock price today?

One share of Tenax Therapeutics stock can currently be purchased for approximately $0.25.

How big of a company is Tenax Therapeutics?

Tenax Therapeutics has a market capitalization of $9.46 million and generates $40,000.00 in revenue each year. The specialty pharmaceutical company earns $-43,920,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis. Tenax Therapeutics employs 11 workers across the globe.

How can I contact Tenax Therapeutics?

Tenax Therapeutics' mailing address is ONE COPLEY PARKWAY SUITE 490, MORRISVILLE NC, 27560. The specialty pharmaceutical company can be reached via phone at 919-806-4414 or via email at [email protected]


MarketBeat Community Rating for Tenax Therapeutics (TENX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  64 (Vote Outperform)
Underperform Votes:  36 (Vote Underperform)
Total Votes:  100
MarketBeat's community ratings are surveys of what our community members think about Tenax Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Tenax Therapeutics (NASDAQ:TENX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $50.00$50.00$50.00$50.00
Price Target Upside: 409.68% upside409.68% upside409.68% upside409.68% upside

Tenax Therapeutics (NASDAQ:TENX) Consensus Price Target History

Price Target History for Tenax Therapeutics (NASDAQ:TENX)

Tenax Therapeutics (NASDAQ:TENX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/18/2017Ladenburg Thalmann Financial ServicesUpgradeNeutral -> Buy$50.00HighView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Tenax Therapeutics (NASDAQ:TENX) Earnings History and Estimates Chart

Earnings by Quarter for Tenax Therapeutics (NASDAQ:TENX)

Tenax Therapeutics (NASDAQ TENX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/21/2017Q4 2016($2.80)($3.00)ViewN/AView Earnings Details
11/10/2016Q316($3.40)($3.00)ViewListenView Earnings Details
8/9/2016Q2 2016($3.20)($3.40)ViewN/AView Earnings Details
5/10/2016Q1 2016($3.80)ViewN/AView Earnings Details
12/15/2015Q216($2.80)($2.60)ViewListenView Earnings Details
9/14/2015Q116($2.80)($2.20)ViewListenView Earnings Details
7/16/2015Q415($2.80)($3.60)ViewListenView Earnings Details
3/18/2015Q315($3.20)($2.00)ViewN/AView Earnings Details
12/17/2014Q215($3.60)($2.80)ViewN/AView Earnings Details
9/15/2014Q3 2014($1.60)ViewN/AView Earnings Details
3/17/2014($7.60)($2.60)$0.04 millionViewN/AView Earnings Details
12/17/2013Q4 2013($25.00)$0.06 millionViewN/AView Earnings Details
9/17/2013Q3 2013($67.20)$0.04 millionViewN/AView Earnings Details
3/18/2013Q1 2013($56.00)$0.22 millionViewN/AView Earnings Details
12/17/2012Q4 2012($52.00)ViewN/AView Earnings Details
9/19/2012Q3 2012($87.60)ViewN/AView Earnings Details
7/24/2012Q2 2012($44.00)($20.00)ViewN/AView Earnings Details
3/15/2012Q1 2012($48.00)($156.00)ViewN/AView Earnings Details
12/16/2011Q4 2011($40.00)($116.00)ViewN/AView Earnings Details
9/19/2011Q3 2011($40.00)($132.00)ViewN/AView Earnings Details
7/14/2011Q2 2011($40.00)($42.80)ViewN/AView Earnings Details
3/21/2011Q1 2011($40.00)($44.00)ViewN/AView Earnings Details
12/9/2010Q4 2010($52.00)($36.00)ViewN/AView Earnings Details
9/17/2010Q3 2009($4.00)ViewN/AView Earnings Details
9/9/2010Q3 2010($48.00)($52.00)ViewN/AView Earnings Details
3/19/2010Q1 2010($48.00)($53.60)ViewN/AView Earnings Details
12/11/2009Q4 2009($52.80)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Tenax Therapeutics (NASDAQ:TENX) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.35 EPS
Next Year EPS Consensus Estimate: $-0.23 EPS

Dividends

Dividend History for Tenax Therapeutics (NASDAQ:TENX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Tenax Therapeutics (NASDAQ TENX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.92%
Institutional Ownership Percentage: 10.39%
Insider Trades by Quarter for Tenax Therapeutics (NASDAQ:TENX)
Institutional Ownership by Quarter for Tenax Therapeutics (NASDAQ:TENX)

Tenax Therapeutics (NASDAQ TENX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/18/2017Ronald R BlanckDirectorBuy12,950$0.45$5,827.5013,624View SEC Filing  
11/14/2017Ronald R BlanckDirectorSell12,950$0.39$5,050.507,149View SEC Filing  
11/23/2016Gerald T ProehlDirectorBuy29,882$1.67$49,902.9415,433View SEC Filing  
11/19/2015Ronald R BlanckDirectorBuy4,700$3.26$15,322.0012,899View SEC Filing  
1/20/2015Ronald R BlanckDirectorBuy2,000$3.49$6,980.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Tenax Therapeutics (NASDAQ TENX) News Headlines

Source:
DateHeadline
Tenax Therapeutics Announces Reverse Stock SplitTenax Therapeutics Announces Reverse Stock Split
finance.yahoo.com - February 23 at 9:12 AM
World-Recognized Experts Join Tenax Therapeutics’ Scientific Advisory Board to Guide New Phase 2 StudyWorld-Recognized Experts Join Tenax Therapeutics’ Scientific Advisory Board to Guide New Phase 2 Study
finance.yahoo.com - February 6 at 9:15 AM
ValuEngine Upgrades Tenax Therapeutics (TENX) to "Sell"ValuEngine Upgrades Tenax Therapeutics (TENX) to "Sell"
www.americanbankingnews.com - February 4 at 11:54 AM
Tenax Therapeutics (TENX) to Develop Levosimendan for Pulmonary Hypertension IndicationTenax Therapeutics (TENX) to Develop Levosimendan for Pulmonary Hypertension Indication
www.streetinsider.com - January 17 at 11:15 AM
Tenax Therapeutics Announces Plan to Develop Levosimendan for a Pulmonary Hypertension Indication with No FDA Approved TherapiesTenax Therapeutics Announces Plan to Develop Levosimendan for a Pulmonary Hypertension Indication with No FDA Approved Therapies
finance.yahoo.com - January 16 at 11:24 AM
Does Zero-Debt Make Tenax Therapeutics Inc (NASDAQ:TENX) A Financially Strong Company?Does Zero-Debt Make Tenax Therapeutics Inc (NASDAQ:TENX) A Financially Strong Company?
finance.yahoo.com - January 2 at 9:03 PM
How These Biotech Stocks are Performing? -- Agenus, Aptose Biosciences, RXi Pharma, and Tenax TherapeuticsHow These Biotech Stocks are Performing? -- Agenus, Aptose Biosciences, RXi Pharma, and Tenax Therapeutics
www.bizjournals.com - August 4 at 8:54 AM
TENX: FDA Response on LevosimendanTENX: FDA Response on Levosimendan
finance.yahoo.com - August 3 at 7:52 AM
Tenax Therapeutics Provides Regulatory Update on LevosimendanTenax Therapeutics Provides Regulatory Update on Levosimendan
finance.yahoo.com - July 29 at 7:50 AM
Tenax Therapeutics (TENX) Reviews Additional Data with FDA & Potential Levosimendan NDA SubmissionTenax Therapeutics (TENX) Reviews Additional Data with FDA & Potential Levosimendan NDA Submission
www.streetinsider.com - May 16 at 8:10 PM
Tenax Therapeutics (TENX) to Review Strategic Alternatives; CEO ResignsTenax Therapeutics (TENX) to Review Strategic Alternatives; CEO Resigns
www.streetinsider.com - April 7 at 11:21 PM
Tenax Therapeutics (TENX) to Review Strategic Alternatives; CEO Resigns - StreetInsider.comTenax Therapeutics (TENX) to Review Strategic Alternatives; CEO Resigns - StreetInsider.com
www.streetinsider.com - April 7 at 12:58 PM
Tenax Therapeutics (TENX) Offers FY16 Results, Corporate UpdateTenax Therapeutics (TENX) Offers FY16 Results, Corporate Update
www.streetinsider.com - March 22 at 12:57 AM
BUZZ-US STOCKS ON THE MOVE-Banks, Chipotle, Airlines, Pain Therapeutics, Pulmatrix, Sunshine Heart - NasdaqBUZZ-US STOCKS ON THE MOVE-Banks, Chipotle, Airlines, Pain Therapeutics, Pulmatrix, Sunshine Heart - Nasdaq
www.nasdaq.com - March 21 at 7:54 PM
Tenax Therapeutics (TENX) Offers FY16 Results, Corporate Update - StreetInsider.comTenax Therapeutics (TENX) Offers FY16 Results, Corporate Update - StreetInsider.com
www.streetinsider.com - March 21 at 7:54 PM
Q4 2016 Tenax Therapeutics Inc Earnings Release - Before Market OpenQ4 2016 Tenax Therapeutics Inc Earnings Release - Before Market Open
biz.yahoo.com - March 21 at 9:57 AM
TENAX THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or StTENAX THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or St
biz.yahoo.com - March 17 at 8:13 PM
TENAX THERAPEUTICS, INC. Files SEC form 10-K, Annual ReportTENAX THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 16 at 9:13 PM
Tenax Therapeutics Inc. (TENX) Plummeted To A New Low On Study Results - RTT NewsTenax Therapeutics Inc. (TENX) Plummeted To A New Low On Study Results - RTT News
www.rttnews.com - February 3 at 6:11 AM
Tenax Therapeutics Inc. (TENX) Has Plunged To A New Low On Phase 3 Study NewsTenax Therapeutics Inc. (TENX) Has Plunged To A New Low On Phase 3 Study News
www.rttnews.com - February 2 at 5:55 AM
9:00 am Tenax Therapeutics announces top-line results from its Phase 3 LEVO-CTS trial; study did not achieve statistically significant reductions in dual or quad primary endpoints (shares halted)9:00 am Tenax Therapeutics announces top-line results from its Phase 3 LEVO-CTS trial; study did not achieve statistically significant reductions in dual or quad primary endpoints (shares halted)
us.rd.yahoo.com - February 2 at 5:55 AM
Tenax Therapeutics Announces Top-Line Results From Phase 3 LEVO-CTS Trial in Cardiac SurgeryTenax Therapeutics Announces Top-Line Results From Phase 3 LEVO-CTS Trial in Cardiac Surgery
us.rd.yahoo.com - February 2 at 5:55 AM
Tenax Therapeutics (TENX) Says Phase 3 LEVO-CTS Trial in Cardiac Surgery Did Not Achieve Dual Endpoint - StreetInsider.comTenax Therapeutics (TENX) Says Phase 3 LEVO-CTS Trial in Cardiac Surgery Did Not Achieve Dual Endpoint - StreetInsider.com
www.streetinsider.com - February 1 at 6:52 AM
Tenax Therapeutics: Will It Or Wont It?Tenax Therapeutics: Will It Or Won't It?
www.rttnews.com - January 30 at 11:29 AM

SEC Filings

Tenax Therapeutics (NASDAQ:TENX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Tenax Therapeutics (NASDAQ:TENX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Tenax Therapeutics (NASDAQ TENX) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.